Elanco Clarifies Earlier Credelio® CAT (lotilaner) Communications Following National Take Your Cat to Work Day
INDIANAPOLIS, Ind., June 22, 2026 — Earlier today, veterinary professionals and media contacts may have received unusual communications connected to Elanco’s participation in National Take Your Cat to Work Day.
After briefly stepping away from their computers, several Elanco employees returned to discover their cats had taken over the warmest spots in the office — their laptops — resulting in a series of unintended emails, social posts, and draft communications being distributed externally.
Newly Released Footage from this morning
Can't see the video in your browser? If so, please try an alternative browser option to see the chaos unfold!
While the earlier messages may have been difficult to interpret, the intended message behind them remains the same: Credelio Cat is specifically designed for cats.
Credelio Cat is the first and only oral flea & tick tablet specifically developed for cats and was formulated using a novel vanilla aroma and yeast flavoring.i In a U.S. field study, 99.5% of cat owners reported successful administration.*
Through the Trust the Taste campaign, Elanco continues working to address common misconceptions about oral flea & tick medications for cats and to help veterinary professionals reconsider oral administration as a reliable option for feline patients and their owners.
Veterinary professionals can learn more about Credelio Cat and the Trust the Taste campaign by visiting https://my.elanco.com/us/credelio-cat
Indications
Credelio Cat kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) for one month in cats and kittens 8 weeks of age and older and weighing 2.0 lbs or greater.
Credelio Cat is also indicated for treatment and control of Ixodes scapularis (black-legged tick) infestations for one month in cats and kittens 6 months of age and older and weighing 2.0 lbs or greater.
Important Safety Information
Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia and seizures. Neurologic adverse reactions have been reported in cats receiving isoxazoline class drugs, even in cats without a history of neurologic disorders. Use with caution in cats with a history of neurologic disorders. The safety of Credelio Cat has not been established in breeding, pregnant and lactating cats. The effectiveness of Credelio Cat against Ixodes scapularis in kittens less than 6 months of age has not been evaluated. The most frequently reported adverse reactions are weight loss, tachypnea and vomiting. For full prescribing information see the Credelio Cat package insert or visit my.elanco.com/us/credelio-cat for full prescribing information.
Disclaimers and References
*U.S. field study (648 doses, 225 cats): 21.1% accepted from hand, 25.8% taken with food, 52.6% accepted when placed in mouth, 0.5% not administered
iToutain CE, et al. Parasites & Vectors. 2018.
Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates.
© 2026 Elanco or its affiliates. PM-US-26-1044
